Tag: OCC
Orthocell looks to enter US market following positive CelGro study results
Regenerative medicine company Orthocell (ASX: OCC) has completed a US FDA regulatory study demonstrating successful bone growth using its proprietary CelGro technology and intends to leverage the resu...
Orthocell receives patent for breakthrough CelGro ‘collagen rope’ to treat ACL injuries
Regenerative medicine company Orthocell (ASX: OCC) has been granted a key patent for a 16-year period relating to a potential breakthrough CelGro collagen rope device to enhance the surgical repair of...
Orthocell on course to revolutionise nerve regeneration after positive interim clinical results
Regenerative medicine company Orthocell (ASX: OCC) came out of a trading halt this morning with positive interim clinical results for CelGro, a collagen medical device which facilitates tissue repair ...
Orthocell reports high success rate from CelGro surgical trial on patients with rotator cuff injuries
Follow-up results from a CelGro tendon regeneration clinical trial conducted by Perth-based Orthocell (ASX: OCC) has confirmed all patients achieved a successful tendon repair with no need for revisio...
Orthocell’s latest pre-clinical study underlines CelGro performance in nerve repair
Orthocell (ASX: OCC) published yet another batch of trial results relating to CelGro which it says validates its claim that the technique can deliver higher quality nerve repair compared to existing m...
Orthocell’s CelGro bone regeneration device accelerates dental implant treatment timeframes, cuts costs
Orthocell (ASX: OCC) has achieved a substantial reduction in dental implant treatment timeframes during a study using its CelGro regeneration device which facilitates bone and tissue repair and healin...
Orthocell unveils first clinical trial results for nerve regeneration platform CelGro
Regenerative medicine company Orthocell (ASX: OCC) has provided the first batch of evidence supporting the efficacy of its CelGro nerve regeneration platform.
The company published results of the f...
Orthocell hails high success rate for tendon injury treatment
Regenerative medicine company Orthocell (ASX: OCC) has announced results from a recent study that shows an 82% success rate using its novel stem cell therapy treatment for chronic tendon injuries.
...
Orthocell highlights its novel ability to treat tennis elbow
Regenerative medicine company Orthocell (ASX: OCC) has posted positive results from a study into its novel tendon cell therapy treatment for tennis elbow.
Orthocell says that Ortho-ATI is a “world-...
Orthocell looks forward to strong European market after successful clinical study
Emerging biotech company Orthocell (ASX: OCC) has received positive news regarding its CelGro medical device that improves dental bone regeneration.
The clinical study was performed in collaboratio...
Orthocell secures Canadian patent rights for tendon regeneration
Biotechnology focusing on regenerative medicine is making huge strides and setting foot in more countries around the world, this time courtesy of Orthocell (ASX: OCC), a small-cap Perth-based biotech ...
